Heart-Failure Therapy - New Drugs but Old Habits?
Published in The New England journal of medicine
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
...Published in The New England journal of medicine
In patients with type 2 diabetes, inhibitors of sodium-glucose cotransporter 2 (SGLT2) reduce the risk of a first hospitalization for heart failure, possibly through glucose-independent mechanisms. More data are needed regarding the effects of SGLT2 inhibitors in patients with established heart failure and a reduced ejection fraction, regardless of...
Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC.
...Published in The New England journal of medicine
Osimertinib is a third-generation, irreversible tyrosine kinase inhibitor of the epidermal growth factor receptor (EGFR-TKI) that selectively inhibits both EGFR-TKI-sensitizing and EGFR T790M resistance mutations. A phase 3 trial compared first-line osimertinib with other EGFR-TKIs in patients with EGFR mutation-positive advanced non-small-cell lun...
Realizing the Dream of Molecularly Targeted Therapies for Cystic Fibrosis.
Published in The New England journal of medicine
Nintedanib in Progressive Fibrosing Interstitial Lung Diseases.
...Published in The New England journal of medicine
Preclinical data have suggested that nintedanib, an intracellular inhibitor of tyrosine kinases, inhibits processes involved in the progression of lung fibrosis. Although the efficacy of nintedanib has been shown in idiopathic pulmonary fibrosis, its efficacy across a broad range of fibrosing lung diseases is unknown. In this double-blind, placebo-...
Understanding Progressive Fibrosing Interstitial Lung Disease through Therapeutic Trials.
Published in The New England journal of medicine
Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 Diabetes.
...Published in The New England journal of medicine
Closed-loop systems that automate insulin delivery may improve glycemic outcomes in patients with type 1 diabetes. In this 6-month randomized, multicenter trial, patients with type 1 diabetes were assigned in a 2:1 ratio to receive treatment with a closed-loop system (closed-loop group) or a sensor-augmented pump (control group). The primary outcom...
Toward Automated Insulin Delivery.
Published in The New England journal of medicine
Real-Time Digital Surveillance of Vaping-Induced Pulmonary Disease.
Published in The New England journal of medicine
Tennessee's Opening Bid for a Medicaid Block Grant.
Published in The New England journal of medicine
